New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
11:12 EDTJAZZJazz Pharmaceuticals price target lowered to $151 from $182 at Cantor
Cantor believes an overhang remains on Jazz Pharmaceuticals as the company continues to dispute the wording in the final REMS for Xyrem and the firm now sees a lower chance that the company may be taken over in the next year. Cantor lowered its price target on Jazz to $151 from $182 and maintains its Hold rating on the shares.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 11, 2014
16:16 EDTJAZZJazz Pharmaceuticals initiates rolling NDA submission for defibrotide
Subscribe for More Information
December 9, 2014
08:31 EDTJAZZJazz, Concert say Phase 1 JZP-386 evaluation not done at highest dosage
Subscribe for More Information
December 8, 2014
07:29 EDTJAZZUBS to hold investor trip
Subscribe for More Information
07:18 EDTJAZZUBS to hold investor trip
2014 Annual West Coast Investor Trip travels on the West Coast on December 8-10.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use